{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:29:10Z","timestamp":1787938150175,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,15]]},"DOI":"10.1097\/tp.0b013e31819d3353","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T17:12:47Z","timestamp":1242925967000},"page":"1092-1095","source":"Crossref","is-referenced-by-count":52,"title":["Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up"],"prefix":"10.1097","volume":"87","author":[{"given":"Menna R.","family":"Clatworthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy Y.","family":"Calne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perpetua R.U.","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.E.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2930633","article-title":"Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.","volume":"293","author":"Xia","year":"1993","journal-title":"Biochem J"},{"key":"R2-22-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2567.1996.d01-650.x","article-title":"Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.","volume":"88","author":"Brett","year":"1996","journal-title":"Immunology"},{"key":"R3-22-20210129","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.","volume":"44","author":"Issacs","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R4-22-20210129","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/sj.bmt.1703733","article-title":"Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?","volume":"30","author":"Hale","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R5-22-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/10245330400026139","article-title":"A review of Campath in autoimmune disease: Biologic therapy in the gray zone between immunosuppression and immunoablation.","volume":"10","author":"Reiff","year":"2005","journal-title":"Hematology"},{"key":"R6-22-20210129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): A systematic review in organ transplantation.","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"key":"R7-22-20210129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":"Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation\u2014Efficacy and safety at five years.","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"R8-22-20210129","first-page":"12","article-title":"Alemtuzumab as induction therapy in renal transplantation.","volume":"2","author":"Clatworthy","year":"2008","journal-title":"Trends Transplant"},{"key":"R9-22-20210129","first-page":"869","article-title":"Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.","volume":"27","author":"Friend","year":"1995","journal-title":"Transplant Proc"},{"key":"R10-22-20210129","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1399-0012.2004.00288.x","article-title":"Campath and renal transplant rejection.","volume":"18","author":"Thomas","year":"2004","journal-title":"Clin Transplant"},{"key":"R11-22-20210129","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.transproceed.2005.03.042","article-title":"Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.","volume":"37","author":"Csapo","year":"2005","journal-title":"Transplant Proc"},{"key":"R12-22-20210129","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.transproceed.2004.12.019","article-title":"Reversal of acute cellular rejection after renal transplantation with Campath-1H.","volume":"37","author":"Basu","year":"2005","journal-title":"Transplant Proc"},{"key":"R13-22-20210129","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/00007890-199911150-00032","article-title":"Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.","volume":"68","author":"Rebello","year":"1999","journal-title":"Transplantation"},{"key":"R14-22-20210129","first-page":"324","article-title":"Successful reversal of refractory acute rejection with CAMPATH-1H in pancreas transplant recipients.","volume":"3","author":"Potdar","year":"2003","journal-title":"Am J Transplant"},{"key":"R15-22-20210129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/00007890-200209270-00034","article-title":"Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.","volume":"74","author":"Reams","year":"2002","journal-title":"Transplantation"},{"key":"R16-22-20210129","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1600-6143.2004.00518.x","article-title":"Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H.","volume":"4","author":"Schneeberger","year":"2004","journal-title":"Am J Transplant"},{"key":"R17-22-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2006.05.006","article-title":"CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.","volume":"120","author":"Watanabe","year":"2006","journal-title":"Clin Immunol"},{"key":"R18-22-20210129","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1600-6143.2007.02134.x","article-title":"CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.","volume":"8","author":"Bloom","year":"2008","journal-title":"Am J Transplant"},{"key":"R19-22-20210129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R20-22-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","article-title":"Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.","volume":"5","author":"Pearl","year":"2005","journal-title":"Am J Transplant"},{"key":"R21-22-20210129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2007.02078.x","article-title":"Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.","volume":"8","author":"Trzonkowski","year":"2008","journal-title":"Am J Transplant"},{"key":"R22-22-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-6143.2006.01641.x","article-title":"Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab.","volume":"7","author":"Zeevi","year":"2007","journal-title":"Am J Transplant"},{"key":"R23-22-20210129","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","article-title":"Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab.","volume":"6","author":"Kirk","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-22-20210129","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2006-07-035766","article-title":"Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used.","volume":"109","author":"Loh","year":"2007","journal-title":"Blood"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200904150-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:49:17Z","timestamp":1786038557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200904150-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31819d3353","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}